Pathogenesis of parkinson's disease: Dopamine, vesicles and α-synuclein

Nature Reviews Neuroscience

Volumn 3, Issue 12, 2002, Pages 932-942

  Lotharius, Julie ^a,b   Brundin, Patrik ^a  

^a LUND UNIVERSITY   (Sweden)

^b H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; NERVE PROTEIN; SNCA PROTEIN, HUMAN; SYNUCLEIN;

ANIMAL; GENETICS; HUMAN; METABOLISM; PARKINSON DISEASE; PATHOLOGY; REVIEW; SYNAPSE VESICLE;

ALPHA-SYNUCLEIN; ANIMALS; DOPAMINE; HUMANS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; SYNAPTIC VESICLES; SYNUCLEINS;

EID: 0036884733     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn983     Document Type: Article

References (135)

1. Kruger, R., Eberhardt, O., Riess, O., Schulz, J. B. and Riess, O. Parkinson's disease: one biochemical pathway to fit all genes? Trends Mol. Med. 8, 236-240 (2002).
2. Lansbury, P. T. and Brice, A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr. Opin. Genet. Dev. 12, 299-306 (2002).
3. Sherer, T. B., Betarbet, R. and Greenamyre, J. T. Pathogenesis of Parkinson's disease. Curr. Opin. Investig. Drugs 2, 657-662 (2001).
4. Duda, J. E., Giasson, B. I., Mabon, M. E., Lee, V M. and Trojanowski, J. Q. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann. Neuroi. 52, 205-210 (2002).
5. Sauer, H. and Oertel, W. H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59, 401-415 (1994).
6. Lee, C. S., Sauer, H. and Bjorklund, A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 72, 641-653 (1996).
7. Sohal, R. S. and Weindruch, R. Oxidative stress, caloric restriction, and aging. Science 273, 59-63 (1996).
8. Smith, C. D. et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl Acad. Sci. USA 88, 10540-10543 (1991).
9. Mecocci, P. et al. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol. 34, 609-616 (1993).
10. Mecocci, P., MacGarvey, U. and Beal, M. F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36, 747-751 (1994).
11. Lovell, M. A., Ehmann, W. D., Butler, S. M. and Markesbery, W. R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45, 1594-1601 (1995).
12. Marcus, D. L. et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp. Neuroi. 150, 40-44 (1998).
13. Rosen, D. R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62 (1993).
14. Ferrante, R. J. etal. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 69, 2064-2074 (1997).
15. Pedersen, W. A. et al. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann. Neurol. 144, 819-824 (1998).
16. Graham, D. G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633-643 (1978).
17. Maker, H. S., Weiss, C., Silides, D. J. and Cohen, G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J. Neurochem. 36, 589-593 (1981).
18. Halliwell, B. Reactive oxygen species and the central nervous system. J. Neurochem. 59, 1609-1623 (1992).
19. Jenner, P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13 (Suppl. 1), 24-34 (1998).
20. Sofic, E. et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74, 199-205 (1988).
21. Saggu, H. et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53, 692-697 (1989).
22. Dexter, D. T. et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381-389 (1989).
23. Floor, E. and Wetzel, M. G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 70, 2682-2675 (1998).
24. Alam, Z. I. et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69, 1196-1203 (1997).
25. Dexter, D. T. et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 1830-1836 (1989).
26. Yoritaka, A. et al. Immunohistochemical detection of 4- hydroxynonenal protein adducts in Parkinson disease. Proc. NatlAcad. Sci. USA 93, 2696-2701 (1996).
27. Zhang, J. et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 154, 1423-1429 (1999).
28. Alam, Z. I. et al. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69, 1326-1329 (1997).
29. Schulz, J. B., Lindenau, J., Seyfried, J. and Dichgans, J. Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 267, 4904-4911 (2000).
30. Marttila, R. J., Lorentz, H. and Rinne, U. K. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J. Neurol. Sci. 86, 321-331 (1988).
31. Ben-Shachar, D., Riederer, P. and Youdim, M. B. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57, 1609-1614 (1991).
32. Riederer, P. et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520 (1989).
33. Jellinger, K. et al. Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J. Neurochem. 59, 1168-1171 (1992).
34. Dexter, D. T. et al. Nigral dopaminergic cell loss in vitamin E deficient rats. Neuroreport 5, 1773-1776 (1994).
35. Przedborski, S. and Jackson-Lewis, V. Mechanisms of MPTP toxicity. Mov. Disord. 13 (Suppl. 1), 35-38 (1998).
36. 3H]1-methyl-4-phenyl- 2,3-dihydropyridinium ion to mouse striatal membranes: putative vesicular location. Eur. J. Pharmacol. 202, 293-294 (1991).
37. 3H]MPP+ in mouse striatal membranes. Brain Res. 571, 354-357 (1992).
38. Peter, D., Jimenez, J., Liu, Y., Kim, J. and Edwards, R. H. The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J. Biol. Chem. 269, 7231-7237 (1994).
39. Nicklas, W. J., Vyas, I. and Heikkila, R. E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4- phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4- phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36, 2503-2508 (1985).
40. +. Biochem. Biophys. Res. Commun. 134, 743-748 (1986).
41. +) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J. Neurochem. 56, 1184-1190 (1991).
42. Denton, T. and Howard, B. D. A dopaminergic cell line variant resistant to the neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. J. Neurochem. 49, 622-630 (1997).
43. +) involves binding at the same site as the respiratory inhibitor, rotenone. Biochem. Biophys. Res. Commun. 169, 123-128 (1990).
44. Lotharius, J. and O'Malley, K. L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275, 38581-38588 (2000).
45. Jones, S. R., Gainetdinov, R. R., Wightman, R. M. and Caron, M. G. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18, 1979-1986 (1998)
46. Sulzer, D. and Rayport, S. Amphetamine and other. psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 5, 797-808 (1990).
47. Sulzer, D. et ai. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15, 4102-4108 (1995).
48. Seiden, L. S., Commins, D. L., Vosmer, G., Axt, K. and Marek, G. Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projections. Ann. NY Acad. Sci. 537, 161-172 (1998).
49. Sonsalla, P K., Jochnowitz, N. D., Zeevalk, G. D., Oostveen, J. A. and Hall, E. D. Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res. 738, 172-175 (1996).
50. Schmidt, C. J., Ritter, J. K., Sonsalla, P. K., Hanson, G. R. and Gibb, J. W. Role of dopamine in the neurotoxic effects of methamphetamine. J. Pharmacol. Exp. Ther. 233, 539-544 (1985).
51. De Vito, M. J. and Wagner, G. C. Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology 28, 1145-1150 (1989).
52. Cadet, J. L., Ladenheim, B., Baum, I., Carlson, E. and Epstein, C. CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA). Brain Res. 655, 259-262 (1994).
53. Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson s disease. Nature Neurosci. 3, 1301-1306 (2000). 78.
54. McCormack, A. L. et al. Environmental risk factors and Parkinson s disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 10, 119-127 (2002).
55. Fukushima, T., Yamada, K., Isobe, A., Shiwaku, K. and Yamane, Y Mechanism of cytotoxicity of paraquat. I. NADH oxidation and paraquat radical formation via complex I. Exp. Toxicol. Pathol. 45, 345-349 (1993).
56. Lewy, F. in Handbuch der Neurologie Vol. 3 (eds Lewandowski, M. and Abelsdorff, G.) 920-933 (Springer, Berlin, 1912).
57. Goedert, M. α-Synuclein and neurodegenerative diseases. Nature Rev. Neurosci. 2, 492-501 (2001).
58. Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839-840 (1997).
59. George, J. M. The synucleins. Genome Biol. 3, reviews 3002.1-3002.6 (2002).
60. Polymeropoulos, M. H. et al. Mutation in the α-synuclein gene identified in families with Parkinson s disease. Science 84. 276, 2045-2047 (1997).
61. Kruger, R. et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson 's disease. Nature Genet. 18, 106-108 (1998).
62. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998).
63. Giasson, B. I. and Lee, V. M. Parkin and the molecular pathways of Parkinson 's disease. Neuron 31, 885-888 (2001).
64. Leroy, E. et al. The ubiquitin pathway in Parkinson s disease. Nature 395, 451-452 (1998).
65. Liu, Y., Fallon, L., Lashuel, H. A., Liu, Z. and Lansbury, P T. Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and parkinson s disease susceptibility. Cell 111, 209-218 (2002).
66. Kuzuhara, S., Mori, H., Izumiyama, N., Yoshimura, M. and Ihara, Y Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol. (Berl.) 75, 345-353 (1988).
67. Ii, K., Ito, H., Tanaka, K. and Hirano, A. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J. Neuropathol. Exp. Neurol. 56, 125-131 (1997).
68. Auluck, P. K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M. and Bonini, N. M. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson 's disease. Science 295, 865-868 (2002).
69. Galvin, J. E. et al. Monoclonal antibodies to purified cortical Lewy bodies recognize the mid-size neurofilament subunit. Ann. Neurol. 42, 595-603 (1997).
70. Conway, K. A., Harper, J. D. and Lansbury, P. T. Fibrils formed in vitro from a-synuclein and two mutant forms linked to Parkinson s disease are typical amyloid. Biochemistry 39, 2552-2563 (2000).
71. Conway, K. A. et al. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. NatiAcad. Sci. USA 97, 571-576 (2000).
72. Bucciantini, M. et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511 (2002).
73. Goldberg, M. S. and Lansbury, P. T. Jr. Is there a cause-and- effect relationship between α-synuclein fibrillization and Parkinson 's disease? Nature Cell Biol. 2, E115-E119 (2002).
74. Lee, H. J. and Lee, S. J. Characterization of cytoplasmic α-synuclein aggregates: fibril formation is tightly linked to the inclusion forming process in cells. J. Biol. Chem. 25 September 2002 (doi:10.1074/jbc.M208192200).
75. Gosavi, N., Lee, H. J., Lee, J. S., Patel, S. and Lee, S. J. Golgi fragmentation occurs in the cells with prefibrillar α-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 25 September 2002 (doi:10.1074/jbc.M208194200).
76. Tompkins, M. M. and Hill, W. D. Contribution of somal Lewy bodies to neuronal death. Brain Res. 775, 24-29 (1997).
77. Hurtig, H. I. et al. α-Synuclein cortical Lewy bodies correlate with dementia in Parkinson 's disease. Neurology 54, 1916-1921 (2000).
78. Mattila, P M., Rinne, J. O., Helenius, H., Dickson, D. W. and Roytta, M. α-Synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson 's disease. Acta Neuropathoi. (Beri.) 100, 285-290 (2000).
79. Shtilerman, M. D., Ding, T. T. and Lansbury, P. T. Jr. Molecular crowding accelerates fibrillization of a-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson s disease? Biochemistry 41, 3855-3860 (2002).
80. Conway, K. A., Rochet, J. C., Bieganski, R. M. and Lansbury, P T. Jr. Kinetic stabilization of the α-synuclein protofibril by a dopamine-a-synuclein adduct. Science 294, 1346-1349 (2001).
81. Volles, M. J. et al. Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson 's disease. Biochemistry 40, 7812-7819 (2001).
82. Volles, M. J. and Lansbury, P T. Jr. Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson 's disease- linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595-4602 (2002).
83. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T. and Lansbury, P T. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291 (2002).
84. Lashuel, H. et al. α-Synuclein, especially the Parkinson 's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089 (2002).
85. Hashimoto, M. et al. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. Neuroreport 10, 717-721 (1999).
86. Kim, K. S. et al. Aggregation of α-synuclein induced by the Cu, Zn-superoxide dismutase and hydrogen peroxide system. Free Radic. Biol. Med. 32, 544-550 (2002).
87. Sherman, M. Y and Goldberg, A. L. Involvement of molecular chaperones in intracellular protein breakdown. EXS 77, 57-78 (1996).
88. Zhang, Y et al. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Nati Acad. Sci USA 97, 13354-13359 (2000).
89. Shimura, H. et al. Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genet. 25, 302-305 (2000).
90. West, A. B. et al. Functional association of the parkin gene promoter with idiopathic Parkinson 's disease. Hum. Moi. Genet. 11, 2787-2792 (2002).
91. Farrer, M. et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neuroi. 50, 293-300 (2001).
92. Chung, K. K. et al. Parkin ubiquitinates the a-synuclein- interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nature Med. 7, 1144-1150 (2001).
93. Engelender, S. et al. Synphilin-1 associates with a-synuclein and promotes the formation of cytosolic inclusions. Nature Genet. 22, 110-114 (1999).
94. Ribeiro, C. S., Carneiro, K., Ross, C. A., Menezes, J. R. and Engelender, S. Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by α-synuclein. J. Biol. Chem. 277, 23927-23933 (2002).
95. Bence, N. F., Sampat, R. M. and Kopito, R. R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555 (2001).
96. McNaught, K. St P. and Jenner, P. Proteasomal function is impaired in substantia nigra in Parkinson 's disease. Neurosci. Lett. 297, 191-194 (2001).
97. Furukawa, Y et al. Brain proteasomal function in sporadic Parkinson 's disease and related disorders. Ann. Neurol. 51, 779-782 (2002).
98. McNaught, K. S., Belizaire, R., Jenner, P., Olanow, C. W. and Isacson, O. Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson 's disease Neurosci. Lett. 326, 155-158 (2002).
99. Rideout, H. J., Larsen, K. E., Sulzer, D. and Stefanis, L. Proteasomal inhibition leads to formation of ubiquitin/α-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 78, 899-908 (2001).
100. McNaught, K. S. et al. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13, 1437-1441 (2002).
101. McNaught, K. S. et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 81, 301-306 (2002).
102. Abeliovich, A. et al. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252 (2000).
103. Cabin, D. E. et al. Synaptic vesicle depletion in mice lacking α-synuclein. J. Neurosci. 22, 8797-8807 (2002).
104. Dauer, W. et al. Resistance of α-synuclein null mice to the parkinsonism-inducing neurotoxin MPTP Proc. Natl Acad. Sci. USA 99, 14524-14529 (2002).
105. Lotharius, J. et al. Effect of mutant α-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 277, 38884-38894 (2002).
106. Hansson, O. et al. Transgenic mice expressing a Huntington s disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Nati Acad. Sci. USA 96, 8727-8732 (1999).
107. Hansson, O. et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur. J. Neurosci. 14, 1492-1504 (2001).
108. Tyagi, P. and Tayal, G. Ischemic preconditioning of myocardium. Acta Pharmacoi. Sin. 23, 865-870 (2002).
109. Masliah, E. et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269 (2000)
110. Van der Putten, H. et al. Neuropathology in mice expressing human α-synuclein. J. Neurosci. 20, 6021-6029 (2000)
111. Giasson, B. I. et al. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 34, 521-533 (2002).
112. Lee, M. K. et al. Human α-synuclein harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc. Natl Acad. Sci. USA 99, 8968-8973 (2002).
113. Feany, M. B. and Bender, W. W. A Drosophila model of Parkinson's disease. Nature 404, 394-398 (2000).
114. Stein, T. D. and Johnson, J. A. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J. Neurosci. 22, 7380-7388 (2002).
115. Zhou, W., Schaack, J., Zawada, W. M. and Freed, C. R. Overexpression of human α-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res. 926, 42-50 (2002).
116. Xu, J. et al. Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson's disease. Nature Med. 8, 600-606 (2002).
117. Hartmann, A. and Hirsch, E. C. Parkinson's disease. The apoptosis hypothesis revisited. Adv. Neurol. 86, 143-153 (2001).
118. Lee, C. S. et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 47, 493-503 (2000).
119. da Costa, C. A., Ancolio, K. and Checler, F. Wild-type but not Parkinson's disease-related Ala-53 → Thr mutant α-synuclein protects neuronal cells from apoptotic stimuli. J. Biol. Chem. 275, 24065-24069 (2000).
120. Hashimoto, M. et al. α-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress- signaling pathway in neuronal cells. J. Biol. Chem. 277, 11465-11472 (2002).
121. Seo, J. H. et al. α-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 5 September 2002 (doi:10.1096/fj.02-0041fje).
122. Davidson, W. S., Jonas, A., Clayton, D. F. and George, J. M. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449 (1998).
123. Jensen, P. H., Nielsen, M. H., Jakes, R., Dotti, C. G. and Goedert, M. Binding of α-synuclein to rat brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273, 26292-26294 (1998).
124. Jo, E., Fuller, N., Rand, R. P., St George-Hyslop, P. and Fraser, P. E. Defective membrane interactions of familial Parkinson's disease mutant A30P α-synuclein. J. Mol. Biol. 315, 799-807 (2002).
125. Jo, E., McLaurin, J. A., Yip, C. M., St George-Hyslop, P. H. and Fraser, P. α-Synuclein membrane interactions and lipid specificity. J. Biol. Chem. 275, 34328-34334 (2000).
126. Jenco, J. M., Rawlingson, A., Daniels, B. and Morris, A. J. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by α- and β-synuclein. Biochemistry 37, 4901-4909 (1998).
127. Ahn, B. H. et al. α-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. J. Biol. Chem. 277, 12334-12342 (2002).
128. Cockcroft, S. Signalling roles of mammalian phospholipase D1 and D2. Cell. Mol. LifeSci. 58, 1674-1687 (2001).
129. Liscovitch, M., Czarny, M., Fiucci, G. and Tang, X. Phospholipase D: molecular and cell biology of a novel gene family. Biochem. J. 345, 401-415 (2000).
130. Lotharius, J. and Brundin, P. Impaired dopamine storage resulting from α-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum. Mol. Genet. 11, 2395-2407 (2002).
131. Murphy, D. D., Rueter, S. M., Trojanowski, J. Q. and Lee, V. M. Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214-2310 (2000).
132. Kahle, P J. et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365-6373 (2000).
133. Rathke-Hartlieb, S. et al. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant α-synuclein transgenic mice. J. Neurochem. 77, 1181-1184 (2001).
134. Matsuoka, Y. and Vila, M. et al. Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8, 535-539 (2001).
135. Richfield, E. K. et al. Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice. Exp. Neurol. 175, 35-48 (2002)